Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 3/20 | 0.56 |
| ▸ | ADH1A | P07327 | 3/20 | 0.56 |
| ▸ | ADH7 | P40394 | 3/20 | 0.56 |
| ▸ | ADH1C | P00326 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | ADH4 | P08319 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA4 | P22748 | 4/20 | 0.52 |
| ▸ | CA6 | P23280 | 4/20 | 0.52 |
| ▸ | CA5A | P35218 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA3 | P07451 | 3/20 | 0.52 |
| ▸ | F13A1 | P00488 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246326 | 1.00 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL2744454 | 1.00 | — | — | |
| SCHEMBL9556470 | 1.00 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL7238378 | 1.00 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL5255853 | 1.00 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL1314338 | 0.97 | — | — | |
| SCHEMBL790241 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL11441097 | 0.89 | — | — | |
| Iodide SCHEMBL27646334 | 0.89 | — | — | |
| SCHEMBL11322360 | 0.85 | ADH1B (0.72) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4396613-A | DEMYCINOSYLTYLOSIN, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | claimed |
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | disclosed |
| CN-1440382-A | Method for separating ammoniac | BASF AG (DE) | 2003-09-03 | — | — | CN | disclosed |
| US-20030143146-A1 | Method for separating ammoniac | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| US-6200974-B1 | FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT | ZENECA LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | ADH1B 1403/4885ADH1A 293/4885ADH7 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.